¡¶Á½Ð¡ÎÒ˽¼Ò³ÔÒ»¸öbÒ»¸öÄÌÎݸ¡·-ÖÐÎÄBD¸ßÇå°æÕýÔÚ²¥·Å..."/> ÕÔÏØÁî¼·Á˽øÈ¥£¬Ò»¿´Ö®Ï£¬ÂíÉÏã¶×¡ÁË¡£Ö»¼ûɽÇðÉϲ»ÖªºÎʱ·ºÆðÁËÒ»×ùССµÄÍÁµØÃí£¬Ãíǰ»¹Á¢×ÅÒ»¿éʯ±®£¬ÉÏÃæ¿Ì×Å£º¡°ÍÁµØ¹«ÏÔÁ飬»¤ÓÓÒ»·½Æ½°²¡£¡±"/>
¡¶¡¶Á½Ð¡ÎÒ˽¼Ò³ÔÒ»¸öbÒ»¸öÄÌÎݸ¡·-ÖÐÎÄBD¸ßÇå°æÕýÔÚ²¥·Å...¡·¾çÇé¼ò½é£ºÕÔÏØÁî¼·Á˽øÈ¥Ò»¿´Ö®ÏÂÂíÉÏã¶×¡ÁËÖ»¼ûɽÇðÉϲ»ÖªºÎʱ·ºÆðÁËÒ»×ùССµÄÍÁµØÃíÃíǰ»¹Á¢×ÅÒ»¿éʯ±®ÉÏÃæ¿Ì×Å£ºÍÁµØ¹«ÏÔÁ黤ÓÓÒ»·½Æ½°²Îå´óÊØ»¤ÕßËäÈ»µ¥¼òµ¥Ð¡ÎÒ˽¼ÒµÄʵÁ¦Ò»¶¨²»ÈçÊ®´ó¿õÊÀÌì½¾µ«ËûÃÇʤÔÚÊýÄ¿¶àÎåÈËÆë³ö¾ÍËãÒ¶ÌìÒ²²»¸ÒСêï¡¶Á½Ð¡ÎÒ˽¼Ò³ÔÒ»¸öbÒ»¸öÄÌÎݸ¡·-ÖÐÎÄBD¸ßÇå°æÕýÔÚ²¥·Å...µ«¼Íá¶µÈÈËÇÆ¼ûÇØã¡Ô¨µÄÈÝòʱÓÖÊÇÒ»¾ª¿ÉÊǺ¢×ÓµÄâïÊÑÒÀÈ»²»¿Ï·ÅÆúÓÖÔÚICU²¡·¿ÀïסÁËÒ»¸öÔÂÕâôСµÄº¢×Ó´Ó³öÉúÏÕЩ¶¼ÔÚÒ½ÔºÖØÖ¢²¡·¿×Åʵ¿ÉÁ¯
¡¶¡¶Á½Ð¡ÎÒ˽¼Ò³ÔÒ»¸öbÒ»¸öÄÌÎݸ¡·-ÖÐÎÄBD¸ßÇå°æÕýÔÚ²¥·Å...¡·ÊÓÆµËµÃ÷£ºÄ½Èݸ´ÉñÉ«¶ÙʱºÚ³ÉÁ˹øµ×ÄãÔÚ˵ʲôMy lecture was about immunotherapy and transplantation in Hodgkin Lymphoma. What I would like to say is that BV and checkpoint inhibitors, have changed the landscape of treatment for Hodgkin Lymphoma. Hodgkin Lymphoma is currently, let's say, more than 95% of patients, or even higher, can be cured, either in the frontline treatment, first relapse, or second relapse. For first relapse, auto-transplant is still the standard, with the use of immunotherapy before or after auto-transplant For patients who relapse after auto-transplant,allo-transplant is the standard of care, particularly for patients who do not achieve complete remission with immunotherapy.ÁÙÏæÊÐÄôÊÐÕò£ºÖÇÄܽ½¹àµ¾Ì↑ÁÊÕ¸î ÿĶÔö²ú200½ï
¾ÍÔÚ¸Õ¸Õ°¡Ìý·ç»ØÁËÒ»¾äͻȻÏëÆðʲô¶ÔÁËÄÚÀïÉÐÓм¸¸öÊØÎÀ±»É±ÁË" ÎÒÈüÝʻԱϳµ½ÓÊܼì²éËûÖð²½×ßµ½³µÇ°Î¢Î¢ÍäÁËÏÂÑüÊÖ½Ó´¥Ò»Ï³µÅƳµÅÆ×ÖĹØÁ¬Ä¡® E ¡¯¾ÍÄð³ÉÁË¡® L ¡¯" Ãñ¾¯ËµËûÃÇÆäʱ¾Í¸ÐÊÜ²î³Ø¾¢½«¼ÝʻԱ´øÖÁ·±ß½ÓÊÜÊÓ²ì;ÖиüÝʻԱ´Ó¿ã¶µÀïÄóö¹¤¾ßÈû½ø×ìÀïÍÌÏÂÃñ¾¯Á¬Ã¦ÈÃËûͳöÀ´µ«¶Ô·½Ê¸¿Ú·ñ¶¨³ÔϹ¤¾ß
2025-10-15 14:38:35